Inactive Graves’ orbitopathy: to treat or not to treat?
https://doi.org/10.21516/2072-0076-2023-16-1-59-64
Abstract
Purpose: to evaluate the expediency and efficacy of conservative therapy of patients with inactive stages of Graves’ orbitopathy complicated by optical neuropathy. Materials and methods. 62 patients with an inactive stage of Graves’ orbitopathy complicated by optical neuropathy were divided into two groups: group 1 (21 patients, 33.9%) received only symptomatic and local therapy, while group 2 (41 patients, 66.1%) additionally received periorbital injections of glucocorticoid drugs. The patients were examined clinically and instrumentally before and after treatment as well as after a long period of more than 12 months. Results. A positive clinical effect of treatment confirmed by positive dynamics of functional indices of computer perimetry (MS, MD) was achieved in 44 cases (71%), of which 33 patients (75.0% ) belonged to group 2. Positive changes in group 1 were achieved in 52.4% of cases and in group 2 in 80.5% of patients. Long-term results showed stable positive changes in 92.1% of cases. Conclusion. The need for complex therapy, involving local injections of glucocorticoid drugs, of patients in an inactive stage of Grave’s orbitopathy who develop symptoms of optical neuropathy was substantiated.
About the Authors
O. G. PanteleevaRussian Federation
Olga G. Panteleeva — Dr. of Med. Sci., leading researcher, ocular oncology department, associate professor, chair of continuing medical education
14/19, Sadovaya Chernogryazskaya St., Moscow, 105062
F. H. Batyrbekova
Russian Federation
Fatima H. Batyrbekova — ophthalmologist, out-patient department
14/19, Sadovaya Chernogryazskaya St., Moscow, 105062
References
1. Petunina N.A., Truhina L.V., Martirosjan N.S. Endocrine ophthalmopathy: state-of-the-art approaches. Problemy Endokrinologii. 2012; 58 (6): 24–32 (in Russian). https://doi.org/10.14341/probl201258624-32
2. Bartalena L., Baldeschi L., Dickinson A., et al. European Group on Graves’ Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J. Endocrinol. 2008; 158 (3): 273–85. doi: 10.1089/thy.2007.0315
3. Prummel M.F., Wiersinga W.M., Mourits M.P., et al. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch. Intern. Med. 1990; 150 (5): 5: 1098–101. doi:10.1001/archinte.1990.00390170124027
4. Brovkina A.F., Pavlova T.L. Grave`s orbitopathy from the perspective of an ophthalmologist and endocrinologist. Russian journal of clinical ophthalmology. 2000; 1: 11–14 (in Russian).
5. Tallstedt L., Lundell G., Terring O., et al. Thyroid Study Group. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. New Engl. J. Med. 1992; 326 (26): 1733–8. doi: 10.1056/NEJM199206253262603
6. Dedov I.I., Melnichenko G.A., Sviridenko N.J., et al. Federal Clinical Guidelines for the Diagnosis and Treatment of Endocrine Ophthalmopathy in Autoimmune Thyroid Pathology. 2015; 61 (1): 61–74 (in Russian). doi: 10.14341/ probl201561161-74
7. Perros P., Crombie A.L., Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin. Endocrinol. (Oxf). 1995; 42 (1): 45–50. doi: 10.1111/j.1365-2265.1995.tb02597.x
8. Hiromatsu Y., Eguchi H., Tani J., Kasaoka M., Neshima Y. Graves’ ophthalmopathy: epidemiology and natural history. Intern Med. 2014; 53 (5) : 353–60. doi: 10.2169/internalmedicine.53.1518
9. Brovkina A.F., Gusev G.A., Panteleeva O.G. Optical neuropathy in patients with edematous exophthalmos. Russian Journal of Clinical Ophthalmology. 2000: 2: 41–2 (in Russian).
10. Racette L., Fischer M., Bebie H., et al. In: Arefiev Y.A., ed. Visual Field Digest. A review of perimetry methods using the Octopus perimeter as an example. 7rd. ed. Moscow: April; 2018 (in Russian). Avaible by: https://organum-visus.ru/library/sites/library/files/news/pdf/racette_l_et_al_daidzhest_perimetriya_2018.pdf
11. Wiersinga W.M., Kahaly G.J., eds. Management of mild Graves’ orbitopathy: A multidisciplinary approach – questions and answers. In: Graves’ Orbitopathy. Basel: Karger; 2017: 131–9. doi: 10.1159/000475955
12. Douglas R.S., McCoy A.N. Thyroid Eye Disease. New York: Springer; London: Heidelberg Dordrecht; 2015. doi 10.1007/978-1-4939-1746-4
13. Gilbard J.P., Farris R.L. Ocular surface drying and ocular tear film osmolarity in thyroid eye disease. Acta Ophthalmol (Copenh). 1983; 61 (1): 108–16. doi: 10.1111/j.1755-3768.1983.tb01401.x
14. Khumuran A.K., Sunder S., Ahluwalia B.K., Malhotra K.C. Tear film profile in Graves’ ophthalmopathy. Acta Ophthalmol (Copenh). 1992; 70 (3): 346–9. doi: 10.1111/j.1755-3768.1992.tb08576.x
15. Yeatts R.P. Quality of life in patients with Graves ophthalmopathy. Am. Ophthalmol. Soc. 2006; 141 (6): 1175. doi:10.1016/j.ajo.2006.04.012
16. Saakjan S.V., Panteleeva O.G. Systane eye drops in Graves' orbitopathy treatment of thyroid associated ophthalmopathy. Effective pharmacotherapy in endocrinology. 2008; 5: 10–5 (in Russian).
17. Marcocci C.M., Маrino M. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy. Best Pract. Res. Clin. Endocrinol. Metab. 2012; 26 (3): 325–37. doi: 10.1016/j.beem.2011.11.005
18. Marcocci C., Kahaly G.J., Krassas G.E., et al. European Group on Graves' Orbitopathy. Selenium and the course of mild Graves' orbitopathy. N. Engl. J. Med. 2011; 364 (20): 1920–31. doi: 10.1056/NEJMoa1012985
19. Shimanovskij N.L. Glucocorticoid resistance: mechanisms and clinical significance. Farmateka. 2005; 102: (7): 30–3 (in Russian).
20. Dorovskikh V.A., Batalova T.A. Glucocorticoids: from theory to practice: textbook. Blagoveshchensk: AGMA; 2006 (in Russian).
21. Alkawas A.A., Hussein A.M., Shahien E.A. Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy. Clin. Experiment. Ophthalmol. 2010; 38 (7): 692–7. doi: 10.1111/j.1442- 9071.2010.02332.x
22. Hosal B.M., Zilelioglu G. Ocular complication of intralesional corticosteroid injection of a chalazion. Eur. J. Ophthalmol. 2003; 13 (9–10): 798–9. doi: 10.1177/1120672103013009-1012
23. Akduman L., Kolker A.E., Black D.L., Del Priore L.V., Rfplan H.J. Treatment of persistent glaucoma secondary to periocular corticosteroids. Am. J. Ophthalmol. 1996; 122 (2): 275–7. doi: 10.1016/s0002-9394(14)72027-6
24. Moshfeghi D.M., Lowder C.Y., Roth D.B., Kaiser P.K. Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am. J. Ophthalmol. 2002; 134 (1): 132–4. doi: 10.1016/s0002- 9394(02)01426-5
25. Smith J.R., George R.K., Rosenbaum J.T. Lower eyelid herniation of orbital fat may complicate periocular corticosteroid injection. Am. J. Ophthalmol. 2002; 133 (6): 845–7. doi: 10.1016/s0002-9394(02)01412-5
26. Goldberg R.A. Orbital steroid injections. Br. J. Ophthalmol. 2004; 88 (11): 1359–60. doi: 10.1136/bjo.2004.051755
27. Alkawas A.A., Hussein A.M., Shahien E.A. Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy. Clin. Experiment. Ophthalmol. 2010; 38 (7): 692–7. doi: 10.1111/j.1442- 9071.2010.02332.x
28. Panteleeva O.G. The modern concept of the mechanism of development of visual impairment visual functions in Graves' orbitopathy. International Journal of Endocrinology. 2010; 3 (27): 117–22 (in Russian).
29. Sheremet N.L., Kozlova I.V., Akopian A.I., Antonov A.A. Optical neuropathies of different etiology and normal tension glaucoma: the point of differential diagnosis. Vestnik oftal’mologii. 2011; 127 (6): 6–10 (in Russian).
30. Anuchit Poonyathalang, Pisit Preechawat, Warangkhana Charoenkul. Retrobulbar injection of triamcinolone in thyroid associated orbitopathy. J. Med. Assoc Thai. 2005; 88 (3): 345–9.
31. Ebner R., Devoto M.H., Weil D., et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br. J. Ophthalmol. 2004; 88 (11): 1380–6. doi: 10.1136/bjo.2004.046193
Review
For citations:
Panteleeva O.G., Batyrbekova F.H. Inactive Graves’ orbitopathy: to treat or not to treat? Russian Ophthalmological Journal. 2023;16(1):59-64. (In Russ.) https://doi.org/10.21516/2072-0076-2023-16-1-59-64